Source:http://linkedlifedata.com/resource/pubmed/id/14565655
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2003-10-20
|
| pubmed:abstractText |
CPT11, a camptothecin analogue, is a specific DNA topoisomerase I inhibitor, with activity in tumor cell lines with MDR expression. CPT11 has a broad spectrum of activity in solid tumors (especially in colorectal, gastric and small cell lung cancers). Early reports have shown that CPT11 could be active in non-Hodgkin's lymphomas (NHL) with low-dose schedules. To further evaluate the efficacy and toxicity of CPT11 in patients with refractory or relapsed NHLs, we conducted a phase II trial with escalated doses. PATIENTS AND THERAPY: From 04/98 to 05/01, 28 patients with NHL were enrolled. PATIENTS CHARACTERISTICS: M/F 21/7; median age: 56 years (range 28-72); Ann Arbor stage at the time of the study I/II and III/IV in 6 and 21 patients, respectively. Sixteen patients had refractory disease when they were enrolled in this phase II study and 8 patients were previously treated with high-dose therapy and stem-cell transplantation. CPT11 was administrated at the doses of 350 mg/m2 every 3 weeks. Six courses were given in patients who achieved CR, PR or stable disease. Patients were evaluated every 2 courses. If no grade II or more toxicity was observed after the first course, escalated dose (500 mg/m2) was then undertaken. RESULTS: 19/28 patients received more than 2 courses of CPT11 and were evaluated for response. Nine patients received one course of therapy because of either progressive disease (n = 6), toxicity (n = 2) or refusal (n = 1). Ten patients received escalated dose (500 mg/m2). Complete remission and partial was achieved in 2/19 patients, stable disease in 7/19, and progressive disease in 10/19 patients. Median duration of responses was short (3 months, range 1-8 months). Seventy-five courses were evaluated for toxicity according to the WHO criteria. Diarrhea grade 2 or 3 occurred in 9/75 courses; cholinergic syndrome grade 2 in 3/75 courses; nausea grade 3 in 7/75 courses. Hematological toxicity: leucopenia grade 3 or 4 in 21/75 courses; thrombocytopenia grade 3 in 8/75 courses; infectious episodes grade 2 or 3 in 7/75 courses. In 2/7 courses with escalated doses, grade I/IV neutropenia occurred withoutother major toxicity. CONCLUSION: CPT11 has low activity in heavily pretreated NHLs. Responses were of short duration.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Topoisomerase I Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1042-8194
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1529-33
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:14565655-Adult,
pubmed-meshheading:14565655-Aged,
pubmed-meshheading:14565655-Antineoplastic Agents,
pubmed-meshheading:14565655-Camptothecin,
pubmed-meshheading:14565655-Clinical Trials, Phase II as Topic,
pubmed-meshheading:14565655-Diarrhea,
pubmed-meshheading:14565655-Drug Resistance, Neoplasm,
pubmed-meshheading:14565655-Enzyme Inhibitors,
pubmed-meshheading:14565655-Female,
pubmed-meshheading:14565655-Humans,
pubmed-meshheading:14565655-Life Tables,
pubmed-meshheading:14565655-Lymphoma, Non-Hodgkin,
pubmed-meshheading:14565655-Male,
pubmed-meshheading:14565655-Middle Aged,
pubmed-meshheading:14565655-Neoplasm Proteins,
pubmed-meshheading:14565655-Neutropenia,
pubmed-meshheading:14565655-Recurrence,
pubmed-meshheading:14565655-Salvage Therapy,
pubmed-meshheading:14565655-Survival Analysis,
pubmed-meshheading:14565655-Topoisomerase I Inhibitors,
pubmed-meshheading:14565655-Treatment Outcome
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
|
| pubmed:affiliation |
Department de Médecine, Institut Gustave-Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France. ribrag@igr.fr
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Clinical Trial, Phase II
|